Lantern Pharma Hits Key Milestone in Developing Molecular Diagnostic for Oncology Trials with LP-184
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using AI and machine learning to revolutionize oncology drug discovery and development, announced a significant step forward in developing a diagnostic for its drug candidate LP-184. This diagnostic, based on qRT-PCR technology, measures PTGR1 RNA levels in tumor samples to evaluate potential sensitivity to LP-184. Lantern Pharma plans to further develop and validate this assay for use in patient selection for later-stage clinical trials across various solid tumors sensitive to LP-184.
Lantern Pharma Hits Key Milestone in Developing Molecular Diagnostic for Oncology Trials with LP-184